Premium
STEMIs and Coumadin: Are they an unsafe combination?
Author(s) -
Montgomery Jana E.,
Levy Michael S.
Publication year - 2019
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.28056
Subject(s) - medicine , mace , anticoagulant therapy , cardiology , surrogate endpoint , anticoagulant , intensive care medicine , percutaneous coronary intervention , myocardial infarction
Key Points Therapeutic anticoagulation may be a surrogate marker for increased MACE in the setting of a STEMI. Consideration should be given to transradial access for patients on anticoagulation. Triple therapy (DAPT plus anticoagulant) should be minimized.